| 1 |
35363301 | Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. | 2022 Jun 1 |
1 |
| 2 |
34439125 | ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer. | 2021 Aug 5 |
1 |
| 3 |
31967357 | Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. | 2020 Apr |
3 |
| 4 |
32042320 | Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. | 2020 |
2 |
| 5 |
32205016 | A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. | 2020 May |
1 |
| 6 |
29220539 | Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. | 2018 Jun |
1 |
| 7 |
26712685 | Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. | 2016 Jun 1 |
1 |